

# Simon Tiberi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2119281/publications.pdf>

Version: 2024-02-01

173  
papers

6,630  
citations

61984

43  
h-index

76900

74  
g-index

177  
all docs

177  
docs citations

177  
times ranked

5793  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series. <i>Pulmonology</i> , 2022, 28, 155-157.	2.1	1
2	History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. <i>Presse Medicale</i> , 2022, 51, 104112.	1.9	9
3	Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. <i>Pulmonology</i> , 2022, 28, 297-309.	2.1	6
4	Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. <i>International Journal of Infectious Diseases</i> , 2022, 124, S104-S106.	3.3	10
5	Clinical standards for the diagnosis, treatment and prevention of TB infection. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 190-205.	1.2	29
6	World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2022, 124, S1-S3.	3.3	15
7	Drug resistant TB – latest developments in epidemiology, diagnostics and management. <i>International Journal of Infectious Diseases</i> , 2022, 124, S20-S25.	3.3	37
8	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
9	The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1047-1049.	6.0	2
10	The war in Ukraine and potential consequences for the TB epidemic in Europe. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 470-471.	1.2	8
11	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388.	6.7	15
12	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
13	Case studies to illustrate good practice in the management of non-tuberculous mycobacterial pulmonary disease. <i>Respiratory Medicine Case Reports</i> , 2022, 38, 101668.	0.4	1
14	Clinical standards for the dosing and management of TB drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 483-499.	1.2	22
15	Clinical standards for drug-susceptible pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 592-604.	1.2	6
16	WHO drug-resistant TB guidelines 2022: what is new?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 590-591.	1.2	14
17	Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. <i>Pulmonology</i> , 2021, 27, 94-96.	2.1	10
18	TB management in the European Union/European Economic Area: a multi-centre survey. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 126-133.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Atypical mycobacterial infections – management and when to treat. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 216-223.	2.6	11
20	Different disease, same challenges: Social determinants of tuberculosis and COVID-19. <i>Pulmonology</i> , 2021, 27, 338-344.	2.1	35
21	World Tuberculosis Day 2021 Theme – “The Clock is Ticking™” and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S1-S6.	3.3	10
22	Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study. <i>European Respiratory Journal</i> , 2021, 57, 2003831.	6.7	4
23	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	2.1	172
24	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021, 60, 711-725.	3.5	23
25	Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S96-S99.	3.3	32
26	Global Tuberculosis Report 2020 – “Reflections on the Global TB burden, treatment and prevention efforts. <i>International Journal of Infectious Diseases</i> , 2021, 113, S7-S12.	3.3	526
27	Post-TB disease: a new topic for investigation” and why it matters. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 258-261.	1.2	6
28	Delayed-onset myocarditis following COVID-19. <i>Lancet Respiratory Medicine</i> , 2021, 9, e32-e34.	10.7	54
29	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	2.1	18
30	Diagnostic pitfalls of urogenital tuberculosis. <i>Tropical Medicine and International Health</i> , 2021, 26, 753-759.	2.3	7
31	The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 358-366.	1.2	3
32	Exploring a combined biomarker for tuberculosis treatment response: protocol for a prospective observational cohort study. <i>BMJ Open</i> , 2021, 11, e052885.	1.9	0
33	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
34	Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 713-722.	5.6	22
35	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. <i>Pulmonology</i> , 2021, 27, 403-412.	2.1	30
36	A case of Clival Tuberculosis and associated meningitis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 25, 100273.	1.3	2

#	ARTICLE	IF	CITATIONS
37	P158â€¦Extra-pulmonary tuberculosis (EPTB): a comparison between UK-born and foreign-born populations in East London. , 2021, , .		0
38	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. International Journal of Tuberculosis and Lung Disease, 2021, 25, 797-813.	1.2	78
39	Multi-drug Resistant Tuberculosis Management. , 2021, , 279-294.		1
40	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics, 2021, 10, 1355.	3.7	5
41	Breast tuberculosis in East London: A 13â€¦year retrospective observational study. Breast Journal, 2020, 26, 235-239.	1.0	6
42	What is the best regimen to treat latent tuberculosis infection?. Lancet Infectious Diseases, The, 2020, 20, 263-264.	9.1	0
43	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. European Respiratory Journal, 2020, 55, 1901908.	6.7	11
44	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, Januaryâ€¦April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	4.3	133
45	Intermittent regimens for tuberculosis treatment: Back to the Future?. European Respiratory Journal, 2020, 56, 2002510.	6.7	0
46	COVID-19 and tuberculosisâ€¦threats and opportunities. International Journal of Tuberculosis and Lung Disease, 2020, 24, 757-760.	1.2	45
47	Green Light Committee and drug-resistant-tuberculosis: how to address the new challenges?. International Journal of Tuberculosis and Lung Disease, 2020, 24, 539-539.	1.2	0
48	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	6.7	273
49	Tuberculosis in the time of COVID-19: quality of life and digital innovation. European Respiratory Journal, 2020, 56, 2001998.	6.7	28
50	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open, 2020, 10, e035350.	1.9	4
51	Evaluation of the BD MAXâ€¦ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1321-1327.	2.9	14
52	Commemorating World TB Day 2020: â€œItâ€™s TIMEâ€¦â€ Itâ€™s time to End the Global TB Epidemic. International Journal of Infectious Diseases, 2020, 92, S1-S4.	3.3	6
53	On tuberculosis and COVID-19 co-infection. European Respiratory Journal, 2020, 56, 2002328.	6.7	93
54	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	6.7	89

#	ARTICLE	IF	CITATIONS
55	Extraspinal articular tuberculosis: An 11-year retrospective study of demographic features and clinical outcomes in East London. <i>Journal of Infection</i> , 2020, 81, 383-389.	3.3	2
56	Non-tuberculous mycobacterial infections – A neglected and emerging problem. <i>International Journal of Infectious Diseases</i> , 2020, 92, S46-S50.	3.3	46
57	A postgraduate qualification in tuberculosis – Message in a bottle. <i>International Journal of Infectious Diseases</i> , 2020, 92, S100-S102.	3.3	1
58	Post tuberculosis treatment infectious complications. <i>International Journal of Infectious Diseases</i> , 2020, 92, S41-S45.	3.3	36
59	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
60	Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. <i>International Journal of Infectious Diseases</i> , 2020, 92, S10-S14.	3.3	20
61	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	3.3	13
62	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
63	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2734.	2.5	8
64	Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 960-964.	1.4	34
65	The need for pulmonary rehabilitation following tuberculosis treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 720-722.	1.2	25
66	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	3.3	30
67	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55
68	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	6.7	113
69	Multidrug and Extensively Drug-resistant Tuberculosis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 1063-1085.	5.1	25
70	Burden and Characteristics of the Comorbidity Tuberculosis – Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.9	12
71	Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. <i>European Respiratory Review</i> , 2019, 28, 190035.	7.1	107
72	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	3.3	41

#	ARTICLE	IF	CITATIONS
73	Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180324.	0.7	27
74	Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. <i>International Journal of Infectious Diseases</i> , 2019, 80, S68-S72.	3.3	21
75	World Tuberculosis Day March 24th 2019 Theme: – TIME – International Journal of Infectious Diseases Tuberculosis Theme Series. <i>International Journal of Infectious Diseases</i> , 2019, 80, S1-S5.	3.3	3
76	P209 – Chest wall tuberculosis presentations in east london. , 2019, , .		0
77	Necrotizing pneumonia (aetiology, clinical features and management). <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 225-232.	2.6	23
78	Regimen design and pharmacokinetic – pharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 3-4.	9.1	0
79	Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190043.	0.7	5
80	Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 379-386.	5.6	27
81	Single-center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12880.	1.7	16
82	New drugs and perspectives for new anti-tuberculosis regimens. <i>Pulmonology</i> , 2018, 24, 86-98.	2.1	114
83	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 – update. <i>European Respiratory Journal</i> , 2018, 51, 1702678.	6.7	50
84	Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 480-481.	9.1	10
85	Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. <i>Pulmonology</i> , 2018, 24, 132-141.	2.1	19
86	Defining the best regimen to treat isoniazid-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 233-235.	10.7	1
87	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702187.	6.7	1
88	Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!. <i>EBioMedicine</i> , 2018, 29, 11-12.	6.1	5
89	Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 – Wanted: Leaders for a TB-Free World. You can make history. End TB. <i>International Journal of Infectious Diseases</i> , 2018, 68, 122-124.	3.3	9
90	Shigellosis and toxic megacolon secondary to <i>Shigella flexneri</i> serotype 3a: The challenges of laboratory diagnosis. <i>International Journal of Infectious Diseases</i> , 2018, 70, 104-106.	3.3	6

#	ARTICLE	IF	CITATIONS
91	Accelerating the development of therapeutic strategies for drug-resistant tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 607-608.	46.4	26
92	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e198.	9.1	281
93	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1755-1762.	3.0	32
94	The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control. <i>Journal of Critical Care</i> , 2018, 45, 184-196.	2.2	22
95	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet</i> , The, 2018, 392, 821-834.	13.7	452
96	Prognostic value of interferon- $\gamma$ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1077-1087.	9.1	135
97	Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	131
98	Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1164-1170.	6.0	60
99	Non-tuberculous mycobacterial pulmonary disease: a clinical update. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, C118-C122.	0.5	0
100	QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. <i>European Respiratory Journal</i> , 2018, 52, 1800537.	6.7	34
101	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800934.	6.7	59
102	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	7.1	76
103	A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016. <i>Eurosurveillance</i> , 2018, 23, .	7.0	71
104	Imaging features and diagnosis of tuberculosis of the breast. <i>Clinical Radiology</i> , 2017, 72, 217-222.	1.1	22
105	The cursed duet today: Tuberculosis and HIV-coinfection. <i>Presse Medicale</i> , 2017, 46, e23-e39.	1.9	50
106	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	6.7	233
107	Treatment outcomes of MDR-TB and HIV co-infection in Europe. <i>European Respiratory Journal</i> , 2017, 49, 1602363.	6.7	17
108	Intestinal tuberculosis: a diagnostic challenge. <i>Tropical Medicine and International Health</i> , 2017, 22, 994-999.	2.3	51

#	ARTICLE	IF	CITATIONS
109	Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1222-1224.	5.6	11
110	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601612.	6.7	16
111	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 688-694.	2.5	35
112	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. Respiratory Medicine, 2017, 132, 68-75.	2.9	7
113	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490.	5.6	2
114	Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?. International Journal of Infectious Diseases, 2017, 65, 133-134.	3.3	3
115	Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. European Respiratory Journal, 2017, 50, 1701462.	6.7	103
116	Applicability of the shorter "Bangladesh regimen"™ in high multidrug-resistant tuberculosis settings. International Journal of Infectious Diseases, 2017, 56, 190-193.	3.3	38
117	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. Expert Review of Anti-Infective Therapy, 2017, 15, 11-21.	4.4	19
118	Classifying new anti-tuberculosis drugs: rationale and future perspectives. International Journal of Infectious Diseases, 2017, 56, 181-184.	3.3	82
119	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. Clinical Infectious Diseases, 2017, 64, 104-105.	5.8	36
120	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2017, 23, 1718-1721.	4.3	43
121	Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2017, 18, 341.	4.1	47
122	Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Journal of Thoracic Disease, 2017, 9, 2093-2101.	1.4	52
123	Post-implementation blues: the unfulfilled potential of Xpert. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1073-1073.	1.2	1
124	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
125	Retrospective Cohort Study over a period of 5 years of Spinal Tuberculosis at a large London Tertiary Centre. , 2017, , .		0
126	Tb or not Tb; that is the paradoxical reaction. , 2017, , .		0



#	ARTICLE	IF	CITATIONS
127	Five year Cohort Analysis of Non-Tuberculosis Mycobacterium Lung Disease at a Tertiary Referral Centre. , 2017, , .		0
128	P118â€¦How do foreign-born patients with tuberculosis access healthcare? a cohort analysis of referrals from general practice and the emergency department to a tertiary tuberculosis service. Thorax, 2016, 71, A147.1-A147.	5.6	0
129	Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. Journal of Thoracic Disease, 2016, 8, 2666-2671.	1.4	39
130	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 373.	4.1	75
131	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. European Respiratory Journal, 2016, 47, 1288-1290.	6.7	12
132	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	6.7	69
133	Faster for less: the new â€œshorterâ€• regimen for multidrug-resistant tuberculosis. European Respiratory Journal, 2016, 48, 1503-1507.	6.7	66
134	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. European Respiratory Journal, 2016, 48, 1230-1233.	6.7	5
135	Treatment Outcomes in Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2016, 375, 1103-1105.	27.0	73
136	WHO recommendations for multidrug-resistant tuberculosis â€œ Authorsâ€™ reply. Lancet, The, 2016, 388, 2234-2235.	13.7	1
137	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. European Respiratory Journal, 2016, 48, 1527-1529.	6.7	28
138	WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet, The, 2016, 387, 2486-2487.	13.7	47
139	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Review of Clinical Pharmacology, 2016, 9, 1025-1037.	3.1	19
140	First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. European Respiratory Journal, 2016, 48, 935-938.	6.7	84
141	Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. European Respiratory Journal, 2016, 47, 664-667.	6.7	23
142	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	5.8	34
143	The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem. Clinical Infectious Diseases, 2016, 62, 1466-1467.	5.8	5
144	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	6.7	92

#	ARTICLE	IF	CITATIONS
145	Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. <i>European Respiratory Journal</i> , 2016, 47, 333-336.	6.7	64
146	Socio-demographic and clinical characteristics of patients with tuberculosis and diabetes in European countries. <i>A TB-net study.</i> , 2016, , .		0
147	Breast tuberculosis in East London. , 2016, , .		0
148	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , 2016, , .		0
149	Cohort analysis of a large community-based latent tuberculosis screening and treatment programme in a high incidence setting in East London. , 2016, , .		0
150	A retrospective case series: Bone and joint TB in North East London. , 2016, , .		0
151	Oesophageal perforation secondary to tuberculous lymphadenitis: Experience of a tertiary centre. , 2016, , .		0
152	Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis. , 2016, , .		0
153	Giant thoracic aorta aneurysm causing airway and esophagus stenosis. <i>Monaldi Archives for Chest Disease</i> , 2015, 77, 145-6.	0.6	0
154	Multidrug-Resistant Tuberculosis in Europe, 2010â€“2011. <i>Emerging Infectious Diseases</i> , 2015, 21, 409-416.	4.3	75
155	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	6.7	47
156	Inverse psoriasis. <i>Clinical Medicine</i> , 2015, 15, 311.	1.9	5
157	Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1524-1527.	1.2	23
158	Back pain, leg swelling and a cardiac arrest: an interesting case of endocarditis. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202215-bcr2013202215.	0.5	7
159	Bronchopleural fistula, tuberculous empyema and bilateral lung destruction treated in various stages by medical and surgical intervention. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 30, 241-243.	0.6	2
160	ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases. <i>European Respiratory Journal</i> , 2014, 43, 286-289.	6.7	32
161	Protecting ourselves from tuberculosis. Describing a historic poster printed in Italy on 1937. <i>Lung India</i> , 2014, 31, 425.	0.7	1
162	Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. <i>European Respiratory Journal</i> , 2014, 43, 289-292.	6.7	54

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of meropenem+clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. <i>European Respiratory Journal</i> , 2013, 41, 1386-1392.	6.7	145
164	Differential diagnosis of a palmar and plantar rash. <i>BMJ, The</i> , 2013, 347, f5542-f5542.	6.0	0
165	Tuberculosis a re-emerging disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 185-187.	2.0	12
166	A strange case of waitress headache. <i>Lancet, The</i> , 2011, 378, 1824.	13.7	4
167	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	3.1	4
168	Offer of rapid testing and alternative biological samples as practical tools to implement HIV screening programs. <i>New Microbiologica</i> , 2009, 32, 391-6.	0.1	11
169	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	5.0	17
170	Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. <i>New Microbiologica</i> , 2005, 28, 119-25.	0.1	15
171	Endomysial versus gliadin antibodies in diagnosis of coeliac disease in short children with no gastrointestinal symptoms. <i>Lancet, The</i> , 1991, 338, 521.	13.7	6
172	New and repurposed drugs. , 0 , 179-204.		4
173	Clinical cases. , 0 , 446-460.		0